ProCE Banner Activity

Parenteral Prostacyclins in PAH

Clinical Thought
What is the role of IV therapies and how should they be used?

Released: March 26, 2021

Expiration: March 25, 2022

No longer available for credit.

Share

Faculty

James C. Coons

James C. Coons, PharmD, FCCP, BCCP

Associate Professor
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
University of Pittsburgh Medical Center-Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania

Martha Kingman

Martha Kingman, DNP, FNP-C

Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Vallerie V. McLaughlin

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Actelion Pharmaceuticals a Janssen Pharm JJ

Faculty Disclosure

Primary Author

James C. Coons, PharmD, FCCP, BCCP

Associate Professor
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
University of Pittsburgh Medical Center-Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania

James C. Coons, PharmD, FCCP, BCCP, has conducted contracted research for Pfizer and United Therapeutics; received consulting fees from Alnylam and Bristol Myers Squibb.

Martha Kingman, DNP, FNP-C

Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Martha Kingman, DNP, FNP-C, has conducted contracted research for and received consulting fees from Acceleron, Actelion, and United Therapeutics; received consulting fees from Altavant, Caremark, CiVi Biopharma, Gossamer Bio, and Liquidia; conducted contracted research for Reata and Sonavie.

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Vallerie McLaughlin, MD, has received consulting fees from Actelion/J&J, Bayer, and United Therapeutics.